الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
Introduction: Breast cancer is the most common cancer among women in both developed and developing countries accounting for 15-30% in most countries. It’s also occupying 1 st or 2 nd position on leading causes of cancer deaths in most countries. Methods: Pathology review : The electronic medical records available in OCMU system were revised to evaluate the pathology materials and calculate RCB. Gross description and all corresponding slides were underwent a retrospective review by the same pathologist to determine the RCB index and class, and post neoadjuvant pathological stage . Surgical Technique: Type of surgery was tailored according to patient desire and response to neoadjuvant therapy. Statistical Methods: Disease free survival and overall survival were defined from the date of diagnosis using published standardized criteria. Results: All patients irrespective to RCB class showed overall survival for 1 year , while only PCR and RCB –I showed overall survival for study end. With a median 70 months follow-up , 48 patients experienced relapse, and 40 were dead. Among the whole population, RCB was significantly associated with overall survival. 5-years relapse free survival was good in RCB-0 and RCB-1 groups , whereas the prognosis was intermediate in RCB-II patients (39.8%) and poor in RCB-III patients (20.9%). Increasing RCB was associated with an increased risk of poor relapse. Conclusions: Our study as regard RCB class after neoadjuvant , in which luminal tumors were more likely to be classified as RCB-II (49.1%) ,or III (36.9), whereas TNBC or HER2-positive BC were more likely to be RCB-0 or I (45.7% and 52.3% respectively)(p<0.001). only a small subsets of TNBC and HER2-positive breast cancer were classified as RCB-III (13.2% and 8.5% respectively). Keywords: residual cancer burden, Neoadjuvant therapy, breast cancer.